Condition: Alzheimer Disease · Transcranial Magnetic Stimulation · Cerebellum · Sponsor: Xijing Hospital
Alzheimer's Disease (AD) is the primary cause of dementia, with its prominent feature being cognitive decline. The cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention. This study will be conducted to evaluate the efficacy and safety of cerebellar Intermittent theta-burst stimulation (CRB-iTBS) in participants with mild Alzheimer's disease on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 3 months of treatment in the Core Study. This project aims to provide a valid treatment to improve the cognitive function and quality of life for those with Alzheimer's disease.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Xijing Hospital of Air Force Military Medical University | Xi'an, Shaanxi, China | Recruiting |
| Tangdu Hospital of Air Force Military Medical University | Xi'an, Shannxi, China | Recruiting |
| The First Affiliated Hospital of Xi'an Medical University | Xi'an, Shannxi, China | Recruiting |
| The Third Hospital of Xi'an | Xi'an, Shannxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06669182